Revenue
Margin
Demand
Guidance
Tone
Metrics raised 2
- CDMO revenue target raised to beat ₹1,000 crore (from ₹1,000 crore target)
- Indichem semiconductor plant capex completion timeline upgraded to end-Q2 FY27 (ahead of schedule)
Event Participants
Executives
3 Abhishek Patel, Bhavin Shah, Naresh Patel
Analysts
15 Abhigyan Srivastav, Abhijit Akella, Akshay, Archit Joshi, Jason Soans, Juhi Kumari, Krishna Yoga, Manav Kapasi, Nilesh Ghuge, Nupur Kokta, Rikin Shah, Rohit Nagraj, Shreya Banthia, Tirumala Reddy, Vikas Angude
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from operations | ₹329.7 crores | +59.1% YoY; driven by Pharma Intermediates growth (+76.5%) partially offset by Specialty Chemicals commodity phase-out |
| Advanced Pharmaceutical Intermediates revenue | ₹292.7 crores | +76.5% YoY; CDMO grew strongly as expected, core PI also robust on top products and new products gaining volume traction |
| Specialty Chemicals revenue | ₹37 crores | -10.6% YoY; strong BFC recovery offset by commodity chemical decline, in line with expectations |
| Gross profit | ₹190.9 crores | +73% YoY; higher Pharma Intermediates contribution drove the increase |
| Gross margin | 57.9% | +466 bps YoY; driven by higher contribution from Pharma Intermediates business |
| EBITDA | ₹113.1 crores | More than 2x YoY; margin expansion plus operational efficiencies |
| EBITDA margin | 34.3% | +973 bps YoY; expansion driven by gross margin improvement and operational efficiencies |
| PAT | ₹74.9 crores | +70.4% YoY |
| PAT margin | 22.7% | +151 bps YoY |
| Net cash and cash equivalents | ₹314 crores | As on June 30, 2026 |
| Working capital | 99 days | vs 91 days in Q4 FY26; improvement in debtors/creditors offset by higher inventory days |
| Capex (Q1 FY27) | ₹56 crores | ₹15 crores at Indichem; ₹41 crores at ACL (battery chemicals at Jhaghadia, pilot plant at Sachin, maintenance) |
| Capacity utilization | Sachin 83%, Ankleshwar 23%, Jhagadia 55% | Q1 FY27; Sachin nearing utilization roof |
Geographic & Segment Commentary
- Advanced Pharmaceutical Intermediates: Revenue of ₹292.7 crores (+76.5% YoY). CDMO grew strongly year-on-year as expected; core pharmaceutical intermediates also delivered robust growth driven by top products and new products gaining traction. Segment margin ~36%. Four validated CDMO products with regulatory approvals are expected to contribute from H2 FY27, each with peak revenue potential of ₹50-100 crores annually.
- Specialty Chemicals: Revenue of ₹37 crores (-10.6% YoY). Commodity chemicals are being phased out through FY27 and replaced with higher-margin products; strong BFC recovery was offset by commodity decline. Segment margin ~24%. Battery chemicals plant trial run completed with commercial supply started (4,000 MT combined VC/FEC capacity); overall specialty business expected to grow in FY27 despite transition gap.
Company-Specific & Strategic Commentary
- Battery chemicals commercialization: Trial run completed and commercial supply commenced in Q1 FY27. Demand is unprecedented, driven by tight global supply; rapid ramp-up expected through Q2-Q4. Multi-customer base across North America, Korea, and other regions. Third product (Phase 2) capex on track for end-Q2 FY27 with a signed long-term supply contract; fourth product capex to follow contract finalization.
- Semiconductor chemicals (Indichem): AI adoption is structurally driving CPU and memory chip demand while supply remains tight. Indichem plant construction is ahead of schedule, with capex completion expected by end of Q2 FY27 and revenue from FY28. R&D facility already commissioned; margin profile benchmarked to BFC, potentially better. Full capacity targeted in 3-4 years.
- CDMO pipeline development: Company develops 30-40 new molecules annually, submitted to customers at different stages of investigation; healthy RFP activity across CDMO and NCE products. Management is confident of beating the ₹1,000 crore CDMO revenue target. Concentration in the anchor product expected to dilute as new products add to the basket.
- Capacity expansion planning: Sachin plant at 83% utilization (capacity roof); Ankleshwar expected to fill by FY28. Land acquisition planned for a new plant to cover future pharma capacity and newer chemical projects; new R&D center capex to be announced at the appropriate time.
- Portfolio rationalization: Commodity chemicals being phased out in FY27 (a similar exercise was completed for Pharma Intermediates in FY26), replaced with higher-margin products. Minor capex required for plant alignment; a transition gap is expected, but management does not expect Spec Chem revenue to decline for the full year.
- Certifications: Company received Great Place to Work certification and Responsible Care certification from the Indian Chemical Council, reflecting culture and safety/health/environment standards.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue growth | 25% for FY27 (full year) | Reaffirmed by CMD; strong demand environment with healthy RFP activity across CDMO and NCE products |
| EBITDA margin | Similar to FY26 (full year) | Stable margins at a higher revenue base; gross margin expansion helps absorb lower-margin battery mix |
| CDMO revenue | ₹1,000+ crores target; confident to beat | Four validated products contributing from H2 FY27, each generating ₹50-100 crores annually at peak |
| Battery chemicals | Full capacity utilization in ~3 years (by FY29) | Demand not constrained; ramp-up limited only by plant capacity (4,000 MT total for VC + FEC) |
| Indichem semiconductor | Capex completion by end-Q2 FY27; revenue from FY28; full capacity in 3-4 years | R&D facility commissioned with product development underway; new product timelines not committed |
| Electrolyte Phase 2 (third product) | Capex completion by end-Q2 FY27 | On schedule; signed long-term supply contract in place; ramp-up visible in FY28 |
| FY27 capex | ~₹90-95 crores base + additional for R&D/land | ₹50 crores spillover (electrolyte additives, pilot plant) + ₹40-45 crores maintenance; R&D center and land acquisition to be announced |
| Employee cost | ~₹150 crores for FY27 | Includes annual increments and one-time performance bonuses |
Risks & Constraints
| Risk | Context |
|---|---|
| Geopolitical tensions (Gulf) | Raw material availability and supply continuity at risk; management secured RM availability and mitigated logistical challenges in Q1, but tensions persist and remain a watch item |
| Specialty Chemicals transition gap | Commodity chemical phase-out creates a gap before new product ramp-up; minor capex needed to align plants; management expects no full-year Spec Chem revenue decline |
| CDMO revenue concentration | Single anchor molecule drives CDMO concentration; being addressed via 30-40 new molecules annually and four validated products from H2 FY27 |
| Working capital build-up | Working capital at 99 days vs 91 days in Q4 FY26 due to higher inventory; partially offset by improved debtors and creditors |
| Margin dilution from battery mix | Battery chemicals carry lower margins than pharma/CDMO; mix shift could pressure overall EBITDA; management guiding FY26-like margins |
| Customer pipeline dependence | Revenue driven by customer purchase orders; management declined to comment on innovator pipeline (e.g., darolutamide new indications), creating external demand uncertainty |
Q&A Highlights
Battery Chemicals: Commercial Supply & Ramp-Up
- Question: Any revenue recognized this quarter, and what can we work with for the year? (Abhijit Akella)
- Answer: Trial/validation batches completed and commercial supply has started; ramp-up will progress from Q2-Q4. No specific number shared, but supply contracts are in place and management is confident of fast growth. (Abhishek Patel)
- Question: Single or multiple customers, geographies, and peak revenue timeline? (Rohit Nagraj)
- Answer: Multiple customers across North America, Korea, and other regions; full capacity utilization expected in 3 years (FY29). Third product is at the final stage of long-term contract signing; fourth product capex will be planned based on customer quantity requirements. (Abhishek Patel)
Indichem Semiconductor Plant
- Question: Status update, timeline, and product scope for Indichem? (Abhijit Akella, Rikin Shah)
- Answer: Construction is ahead of schedule; capex completion expected by end of Q2 FY27 with revenue from next financial year (FY28). R&D facility commissioned with product development started; photoresist chemicals plus multiple undisclosed projects. Will be a slow start, but full capacity targeted in 3-4 years. (Abhishek Patel)
Margin Guidance & Segment Margins
- Question: What EBITDA margin for FY27? Can margins improve 200-300 bps over 5 years? (Akshay, Manav Kapasi)
- Answer: Full-year FY27 margin will be similar to FY26. Margins are a function of product mix - CDMO contribution is rising but battery carries lower margins; net-net targeting FY26-like EBITDA margin at a higher revenue base; no 5-year margin guidance. (Abhishek Patel)
- Question: Segment-wise margins? (Abhijit Akella)
- Answer: Spec Chem ~24%, Pharma ~36%. (Bhavin Shah)
CDMO: Validated Products & Pipeline
- Question: Timelines for the four validated CDMO products and how much of the ₹1,000 crore target is backed by contracts? (Nupur Kokta)
- Answer: Revenue kicks in from H2 FY27 onwards; each validated product expected to generate ₹50-100 crores per year at peak. (Abhishek Patel)
- Question: How is the pipeline being built beyond the anchor product, and how will concentration be addressed? (Archit Joshi, Tirumala Reddy)
- Answer: Company develops 30-40 molecules annually submitted to customers at various stages; healthy R&D and RFP pipeline; confident of beating the ₹1,000 crore CDMO target. Concentration will dilute as new products add to the basket. (Abhishek Patel, Naresh Patel)
Capex & Expansion Plans
- Question: FY27/FY28 capex and the purpose of land acquisition? (Jason Soans)
- Answer: FY27: ~₹50 crores spillover (electrolyte additives + pilot plant) + ₹40-45 crores maintenance; R&D center and land acquisition capex to be announced later. Land needed for future pharma capacity - Sachin at utilization roof, Ankleshwar expected to fill by FY28. (Abhishek Patel)
Cost Guidance: Employee & Other Expenses
- Question: Employee cost trajectory? (Nilesh Ghuge)
- Answer: ~₹150 crores for FY27, including annual increments and one-time performance bonuses. (Bhavin Shah)
- Question: Other expenses guidance? (Juhi Kumari)
- Answer: In line with previous quarters; savings from solar project and operational efficiencies; similar run rate for rest of FY27. (Bhavin Shah)
Strategic Boundaries: No Forward Integration
- Question: Plans to move into electrolyte salts/solutions or APIs? (Archit Joshi, Tirumala Reddy)
- Answer: No plans to enter LiPF6/electrolyte solutions - sticking to electrolyte additives as core strength. No API forward integration; policy is not to compete with customers. (Abhishek Patel)
Molecule Status Updates
- Question: Status on CAPLYTA and apixaban; is capacity sufficient? (Krishna Yoga)
- Answer: CAPLYTA partner qualified, DMF filed, awaiting product launch. Apixaban already picking up with sufficient capacity to cater to demand. (Naresh Patel, Abhishek Patel)
Revenue Mix Outlook
- Question: How will revenue mix evolve over 3-5 years? (Manav Kapasi)
- Answer: Pharma share expected to move from 87% to ~80% in 3 years as battery and semiconductor grow faster; CDMO also growing fast, so pharma remains dominant. (Abhishek Patel)
Other Income Explanation
- Question: Why did other income drop from ~₹11 crores to ₹1.8 crores? (Abhigyan Srivastav)
- Answer: Q4 FY26 had ~₹10 crores positive euro exchange fluctuation; Q1 FY27 had only ₹10 lakhs positive fluctuation. (Bhavin Shah)
Key Takeaway
Acutaas Chemicals (formerly Ami Organics) delivered a strong Q1 FY27: revenue of ₹329.7 crores (+59.1% YoY), EBITDA of ₹113.1 crores (34.3% margin, +973 bps YoY) and PAT of ₹74.9 crores (+70.4% YoY), driven by 76.5% growth in Advanced Pharmaceutical Intermediates to ₹292.7 crores. Commercial supply commenced from the 4,000 MT battery chemicals plant (VC/FEC), with full utilization targeted by FY29, while the Indichem semiconductor facility is ahead of schedule (capex done by end-Q2 FY27, revenue from FY28). Management reaffirmed 25% FY27 revenue growth with FY26-like margins and expects to beat the ₹1,000 crore CDMO target, backed by four validated products contributing ₹50-100 crores each at peak from H2 FY27. Watch items include Gulf geopolitical tensions affecting raw material supply, the Spec Chem commodity phase-out transition gap, and CDMO anchor product concentration; mitigation includes 30-40 new molecules developed annually and land acquisition for pharma capacity as Sachin runs at 83% utilization.